Chemours has suffered significant stock declines in recent weeks after the company announced that it was delaying the release of its financial results and investigating its internal controls. On February 29, the Company announced its CEO and CFO were placed on administrative leave, and on March 7, the company disclosed that its top executives had manipulated vendor payments and collections of receivables to boost their own bonuses.
Contact our attorneys for a no-cost case evaluation.